GlassScriptPhysician profile
Akhil Vats
NPI 1518199363
$482.28
in general payments reported to CMS, 2019-2025
12 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $127 · 2023: $14.18 · 2024: $48.60 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $217.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $85.73 | 2021-2022 | |
| Pfizer INC. | $74.73 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.86 | 2021 | |
| Novo Nordisk INC | $43.85 | 2025 | Ozempic, Wegovy |
| Corcept Therapeutics | $38.86 | 2025 | Korlym |
| Gilead Sciences, INC. | $36.27 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $35.27 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $32.47 | 2025 | Fanapt |
| Seqirus USA INC | $20.78 | 2025 | Flucelvax, Fluad |
| Heartflow, INC. | $18.38 | 2025 | |
| Antares Pharma, INC. | $15.41 | 2024 | Xyosted |
| Astrazeneca Pharmaceuticals LP | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akhil Vats listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.